226 related articles for article (PubMed ID: 18396360)
1. Long-term immunogenicity of a single dose of acellular pertussis vaccine in paediatric health-care workers.
Littmann M; Hülsse C; Riffelmann M; Wirsing von König CH
Vaccine; 2008 May; 26(19):2344-9. PubMed ID: 18396360
[TBL] [Abstract][Full Text] [Related]
2. Antibody decay after immunisation of health-care workers with an acellular pertussis vaccine.
Riffelmann M; Littmann M; Hülsse C; von König CH
Eur J Clin Microbiol Infect Dis; 2009 Mar; 28(3):275-9. PubMed ID: 18797942
[TBL] [Abstract][Full Text] [Related]
3. Restricted antibody response to Bordetella pertussis filamentous hemagglutinin induced by whole-cell and acellular pertussis vaccines.
Asgarian-Omran H; Golara M; Abdolmaleki S; Navabi SS; Alipour H; Khoshnoodi J; Hemmati A; Zarei S; Jeddi-Tehrani M; Shokri F
Infect Dis (Lond); 2016 Feb; 48(2):127-32. PubMed ID: 26439274
[TBL] [Abstract][Full Text] [Related]
4. Antibody and cell-mediated immunity to pertussis 4 years after monovalent acellular pertussis vaccine at birth.
Wood N; Marshall H; White OJ; Holt PG; McIntyre P
Pediatr Infect Dis J; 2014 May; 33(5):511-7. PubMed ID: 24445839
[TBL] [Abstract][Full Text] [Related]
5. Immunization of teenagers with a fifth dose of reduced DTaP-IPV induces high levels of pertussis antibodies with a significant increase in opsonophagocytic activity.
Aase A; Herstad TK; Merino S; Bolstad M; Sandbu S; Bakke H; Aaberge IS
Clin Vaccine Immunol; 2011 Aug; 18(8):1269-74. PubMed ID: 21677109
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of a three-component acellular pertussis vaccine administered at birth.
Belloni C; De Silvestri A; Tinelli C; Avanzini MA; Marconi M; Strano F; Rondini G; Chirico G
Pediatrics; 2003 May; 111(5 Pt 1):1042-5. PubMed ID: 12728086
[TBL] [Abstract][Full Text] [Related]
7. Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant.
Isaka M; Yasuda Y; Taniguchi T; Kozuka S; Matano K; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
Vaccine; 2003 Mar; 21(11-12):1165-73. PubMed ID: 12559794
[TBL] [Abstract][Full Text] [Related]
8. A novel method for evaluating natural and vaccine induced serological responses to Bordetella pertussis antigens.
Berbers GA; van de Wetering MS; van Gageldonk PG; Schellekens JF; Versteegh FG; Teunis PF
Vaccine; 2013 Aug; 31(36):3732-8. PubMed ID: 23742995
[TBL] [Abstract][Full Text] [Related]
9. A rapid ELISA-based method for screening Bordetella pertussis strain production of antigens included in current acellular pertussis vaccines.
Barkoff AM; Guiso N; Guillot S; Xing D; Markey K; Berbers G; Mertsola J; He Q
J Immunol Methods; 2014 Jun; 408():142-8. PubMed ID: 24925807
[TBL] [Abstract][Full Text] [Related]
10. Antibody persistence after vaccination of adolescents with monovalent and combined acellular pertussis vaccines containing genetically inactivated pertussis toxin: a phase 2/3 randomised, controlled, non-inferiority trial.
Pitisuttithum P; Chokephaibulkit K; Sirivichayakul C; Sricharoenchai S; Dhitavat J; Pitisuthitham A; Phongsamart W; Boonnak K; Lapphra K; Sabmee Y; Wittawatmongkol O; Chauhan M; Wijagkanalan W; Hommalai G; Fortuna L; Chinwangso P; Poredi IK; van den Biggelaar AHJ; Pham HT; Viviani S
Lancet Infect Dis; 2018 Nov; 18(11):1260-1268. PubMed ID: 30266329
[TBL] [Abstract][Full Text] [Related]
11. Boosting Teenagers With Acellular Pertussis Vaccines Containing Recombinant or Chemically Inactivated Pertussis Toxin: A Randomized Clinical Trial.
Blanchard Rohner G; Chatzis O; Chinwangso P; Rohr M; Grillet S; Salomon C; Lemaître B; Boonrak P; Lawpoolsri S; Clutterbuck E; Poredi IK; Wijagkanalan W; Spiegel J; Pham HT; Viviani S; Siegrist CA
Clin Infect Dis; 2019 Mar; 68(7):1213-1222. PubMed ID: 30759183
[TBL] [Abstract][Full Text] [Related]
12. Storage at -3 degrees C for 24 h alters the immunogenicity of pertussis vaccines.
Boros CA; Hanlon M; Gold MS; Roberton DM
Vaccine; 2001 May; 19(25-26):3537-42. PubMed ID: 11348721
[TBL] [Abstract][Full Text] [Related]
13. Differences in avidity of IgG antibodies to pertussis toxin after acellular pertussis booster vaccination and natural infection.
Barkoff AM; Gröndahl-Yli-Hannuksela K; Vuononvirta J; Mertsola J; Kallonen T; He Q
Vaccine; 2012 Nov; 30(48):6897-902. PubMed ID: 22981763
[TBL] [Abstract][Full Text] [Related]
14. Acellular pertussis vaccine at birth and one month induces antibody responses by two months of age.
Wood N; McIntyre P; Marshall H; Roberton D
Pediatr Infect Dis J; 2010 Mar; 29(3):209-15. PubMed ID: 20009964
[TBL] [Abstract][Full Text] [Related]
15. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model.
Kwon HJ; Han SB; Kim BR; Kang KR; Huh DH; Choi GS; Ahn DH; Kang JH
BMC Infect Dis; 2017 Apr; 17(1):247. PubMed ID: 28376777
[TBL] [Abstract][Full Text] [Related]
16. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses.
Cherry JD; Gornbein J; Heininger U; Stehr K
Vaccine; 1998 Dec; 16(20):1901-6. PubMed ID: 9796041
[TBL] [Abstract][Full Text] [Related]
17. Modelling anti-pertussis toxin IgG antibody decay following primary and preschool vaccination with an acellular pertussis vaccine in UK subjects using a modified oral fluid assay.
Fry NK; Litt DJ; Duncan J; Vaghji L; Warrener L; Samuel D; Andrews N; Harnden A; Harrison TG
J Med Microbiol; 2013 Sep; 62(Pt 9):1281-1289. PubMed ID: 23722435
[TBL] [Abstract][Full Text] [Related]
18. Differences of IgG antibody avidity after an acellular pertussis (aP) booster in adolescents after a whole cell (wcP) or aP primary vaccination.
Prelog M; Almanzar G; Rieber N; Ottensmeier B; Zlamy M; Liese J
Vaccine; 2013 Jan; 31(2):387-93. PubMed ID: 23142306
[TBL] [Abstract][Full Text] [Related]
19. Characterization of reference materials for human antiserum to pertussis antigens by an international collaborative study.
Xing D; Wirsing von König CH; Newland P; Riffelmann M; Meade BD; Corbel M; Gaines-Das R
Clin Vaccine Immunol; 2009 Mar; 16(3):303-11. PubMed ID: 19109448
[TBL] [Abstract][Full Text] [Related]
20. Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis.
Trollfors B; Taranger J; Lagergård T; Sundh V; Bryla DA; Schneerson R; Robbins JB
Clin Infect Dis; 1999 Mar; 28(3):552-9. PubMed ID: 10194077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]